Rethinking cancer nanotheranostics

被引:1025
作者
Chen, Hongmin [1 ,3 ]
Zhang, Weizhong [2 ]
Zhu, Guizhi [2 ]
Xie, Jin [2 ,3 ]
Chen, Xiaoyuan [4 ]
机构
[1] Xiamen Univ, Ctr Mol Imaging & Translat Med, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China
[2] Univ Georgia, Dept Chem, Athens, GA 30602 USA
[3] Univ Georgia, Bio Imaging Res Ctr, Athens, GA 30602 USA
[4] Natl Inst Hlth, Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
CELL LUNG-CANCER; CONVECTION-ENHANCED DELIVERY; INTENSITY FOCUSED ULTRASOUND; PHOTODYNAMIC THERAPY; DRUG-DELIVERY; NECK-CANCER; LIPOSOMAL DOXORUBICIN; CONTRAST AGENT; MESSENGER-RNA; VASCULAR NORMALIZATION;
D O I
10.1038/natrevmats.2017.24
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Advances in nanoparticle synthesis and engineering have produced nanoscale agents affording both therapeutic and diagnostic functions that are often referred to by the portmanteau 'nanotheranostics'. The field is associated with many applications in the clinic, especially in cancer management. These include patient stratification, drug-release monitoring, imaging-guided focal therapy and post-treatment response monitoring. Recent advances in nanotheranostics have expanded this notion and enabled the characterization of individual tumours, the prediction of nanoparticle-tumour interactions, and the creation of tailor-designed nanomedicines for individualized treatment. Some of these applications require breaking the dogma that a nanotheranostic must combine both therapeutic and diagnostic agents within a single, physical entity; instead, it can be a general approach in which diagnosis and therapy are interwoven to solve clinical issues and improve treatment outcomes. In this Review, we describe the evolution and state of the art of cancer nanotheranostics, with an emphasis on clinical impact and translation.
引用
收藏
页数:18
相关论文
共 175 条
[1]   Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize [J].
Adams, Stephen R. ;
Yang, Howard C. ;
Savariar, Elamprakash N. ;
Aguilera, Joe ;
Crisp, Jessica L. ;
Jones, Karra A. ;
Whitney, Michael A. ;
Lippman, Scott M. ;
Cohen, Ezra E. W. ;
Tsien, Roger Y. ;
Advani, Sunil J. .
NATURE COMMUNICATIONS, 2016, 7
[2]   Signatures of mutational processes in human cancer [J].
Alexandrov, Ludmil B. ;
Nik-Zainal, Serena ;
Wedge, David C. ;
Aparicio, Samuel A. J. R. ;
Behjati, Sam ;
Biankin, Andrew V. ;
Bignell, Graham R. ;
Bolli, Niccolo ;
Borg, Ake ;
Borresen-Dale, Anne-Lise ;
Boyault, Sandrine ;
Burkhardt, Birgit ;
Butler, Adam P. ;
Caldas, Carlos ;
Davies, Helen R. ;
Desmedt, Christine ;
Eils, Roland ;
Eyfjord, Jorunn Erla ;
Foekens, John A. ;
Greaves, Mel ;
Hosoda, Fumie ;
Hutter, Barbara ;
Ilicic, Tomislav ;
Imbeaud, Sandrine ;
Imielinsk, Marcin ;
Jaeger, Natalie ;
Jones, David T. W. ;
Jones, David ;
Knappskog, Stian ;
Kool, Marcel ;
Lakhani, Sunil R. ;
Lopez-Otin, Carlos ;
Martin, Sancha ;
Munshi, Nikhil C. ;
Nakamura, Hiromi ;
Northcott, Paul A. ;
Pajic, Marina ;
Papaemmanuil, Elli ;
Paradiso, Angelo ;
Pearson, John V. ;
Puente, Xose S. ;
Raine, Keiran ;
Ramakrishna, Manasa ;
Richardson, Andrea L. ;
Richter, Julia ;
Rosenstiel, Philip ;
Schlesner, Matthias ;
Schumacher, Ton N. ;
Span, Paul N. ;
Teague, Jon W. .
NATURE, 2013, 500 (7463) :415-+
[3]   Toward understanding and exploiting tumor heterogeneity [J].
Alizadeh, Ash A. ;
Aranda, Victoria ;
Bardelli, Alberto ;
Blanpain, Cedric ;
Bock, Christoph ;
Borowski, Christine ;
Caldas, Carlos ;
Califano, Andrea ;
Doherty, Michael ;
Elsner, Markus ;
Esteller, Manel ;
Fitzgerald, Rebecca ;
Korbel, Jan O. ;
Lichter, Peter ;
Mason, Christopher E. ;
Navin, Nicholas ;
Pe'er, Dana ;
Polyak, Kornelia ;
Roberts, Charles W. M. ;
Siu, Lillian ;
Snyder, Alexandra ;
Stower, Hannah ;
Swanton, Charles ;
Verhaak, Roel G. W. ;
Zenklusen, Jean C. ;
Zuber, Johannes ;
Zucman-Rossi, Jessica .
NATURE MEDICINE, 2015, 21 (08) :846-853
[4]  
[Anonymous], 2016, NAT REV MATER
[5]   First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial [J].
Arrieta, O. ;
Medina, L. A. ;
Estrada-Lobato, E. ;
Hernandez-Pedro, N. ;
Villanueva-Rodriguez, G. ;
Martinez-Barrera, L. ;
Macedo, E. O. ;
Lopez-Rodriguez, V. ;
Motola-Kuba, D. ;
Corona-Cruz, J. F. .
BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1027-1032
[6]   High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin [J].
Arrieta, Oscar ;
Medina, Luis-Alberto ;
Estrada-Lobato, Enrique ;
Ramirez-Tirado, Laura-Alejandra ;
Mendoza-Garcia, Victor-Osvaldo ;
de la Garza-Salazar, Jaime .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) :211-215
[7]   STING: infection, inflammation and cancer [J].
Barber, Glen N. .
NATURE REVIEWS IMMUNOLOGY, 2015, 15 (12) :760-770
[8]   Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects [J].
Barua, Sutapa ;
Mitragotri, Samir .
NANO TODAY, 2014, 9 (02) :223-243
[9]   Radiation oncology in the era of precision medicine [J].
Baumann, Michael ;
Krause, Mechthild ;
Overgaard, Jens ;
Debus, Juergen ;
Bentzen, Soren M. ;
Daartz, Juliane ;
Richter, Christian ;
Zips, Daniel ;
Bortfeld, Thomas .
NATURE REVIEWS CANCER, 2016, 16 (04) :234-249
[10]   Tumour heterogeneity in the clinic [J].
Bedard, Philippe L. ;
Hansen, Aaron R. ;
Ratain, Mark J. ;
Siu, Lillian L. .
NATURE, 2013, 501 (7467) :355-364